226 related articles for article (PubMed ID: 35728737)
21. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.
Mirzoeva OK; Hann B; Hom YK; Debnath J; Aftab D; Shokat K; Korn WM
J Mol Med (Berl); 2011 Sep; 89(9):877-89. PubMed ID: 21678117
[TBL] [Abstract][Full Text] [Related]
22. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
23. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
24. KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.
Althaiban A; Thyagarajan A; Sahu RP
Mini Rev Med Chem; 2023; 23(8):953-961. PubMed ID: 36573057
[TBL] [Abstract][Full Text] [Related]
25. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
26. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models.
Jiang H; Xu M; Li L; Grierson P; Dodhiawala P; Highkin M; Zhang D; Li Q; Wang-Gillam A; Lim KH
Mol Cancer Ther; 2018 Oct; 17(10):2144-2155. PubMed ID: 30065098
[TBL] [Abstract][Full Text] [Related]
27. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
28. Saikosaponin d modulates the polarization of tumor-associated macrophages by deactivating the PI3K/AKT/mTOR pathway in murine models of pancreatic cancer.
Xu X; Cui L; Zhang L; Yang L; Zhuo Y; Li C
Int Immunopharmacol; 2023 Sep; 122():110579. PubMed ID: 37433245
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract][Full Text] [Related]
30. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract][Full Text] [Related]
31. Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells.
Massoumi RL; Teper Y; Ako S; Ye L; Wang E; Hines OJ; Eibl G
Pancreas; 2021 Apr; 50(4):524-528. PubMed ID: 33939664
[TBL] [Abstract][Full Text] [Related]
32. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
[TBL] [Abstract][Full Text] [Related]
33. High Phosphorylation Status of AKT/mTOR Signal in DESI2-Reduced Pancreatic Ductal Adenocarcinoma.
Shen CC; Cui XY; He Y; Kang YH; Yi C; Yang JL; Gou LT
Pathol Oncol Res; 2015 Apr; 21(2):267-72. PubMed ID: 25079376
[TBL] [Abstract][Full Text] [Related]
34. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
35. New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma.
Golob-Schwarzl N; Puchas P; Gogg-Kamerer M; Weichert W; Göppert B; Haybaeck J
Anticancer Res; 2020 Jun; 40(6):3109-3118. PubMed ID: 32487605
[TBL] [Abstract][Full Text] [Related]
36. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
37. Targeting mTOR dependency in pancreatic cancer.
Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
[TBL] [Abstract][Full Text] [Related]
39. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
40. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
